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Objective: Defective mitochondrial function attributed to optic atrophy 1 (OPA1) mutations causes primarily optic
atrophy and, less commonly, neurodegenerative syndromes. The pathomechanism by which OPA1 mutations trigger
diffuse loss of neurons in some, but not all, patients is unknown. Here, we used a tractable induced pluripotent stem
cell (iPSC)-based model to capture the biology of OPA1 haploinsufficiency in cases presenting with classic eye dis-
ease versus syndromic parkinsonism.
Methods: iPSCs were generated from 2 patients with OPA1 haploinsufficiency and 2 controls and differentiated into
dopaminergic neurons. Metabolic profile was determined by extracellular flux analysis, respiratory complex levels
using immunoblotting, and complex I activity by a colorimetric assay. Mitochondria were examined by transmission
electron microscopy. Mitochondrial DNA copy number and deletions were assayed using long-range PCR. Mitochon-
drial membrane potential was measured by tetramethylrhodamine methyl ester uptake, and mitochondrial fragmen-
tation was assessed by confocal microscopy. Exome sequencing was used to screen for pathogenic variants.
Results: OPA1 haploinsufficient iPSCs differentiated into dopaminergic neurons and exhibited marked reduction in
OPA1 protein levels. Loss of OPA1 caused a late defect in oxidative phosphorylation, reduced complex I levels, and
activity without a significant change in the ultrastructure of mitochondria. Loss of neurons in culture recapitulated
dopaminergic degeneration in syndromic disease and correlated with mitochondrial fragmentation.
Interpretation: OPA1 levels maintain oxidative phosphorylation in iPSC-derived neurons, at least in part, by regulat-
ing the stability of complex I. Severity of OPA1 disease associates primarily with the extent of OPA1-mediated
fusion, suggesting that activation of this mechanism or identification of its genetic modifiers may have therapeutic or
prognostic value.
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Mitochondria form a dynamic network that respondsto physiological signals and stressors by altering
morphology and connectivity to adapt to metabolic
demands in health and disease. A defect in mitochondrial
function has been causatively linked to a variety of
neurodegenerative diseases, the commonest being Parkin-
son’s disease. Optic atrophy 1 (OPA1) is a dynamin-like
GTPase within the inner mitochondrial membrane,
which maintains fusion1 and by assembling into oligom-
ers, keeps the cristae junctions in a closed state.2 These
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core functions of OPA1 appear to be critical for adapta-
tion to bioenergetic demands,3 the control of apoptosis
by limiting cytochrome c mobilization from the cristae
interior,2,4 and, possibly, mitochondrial DNA (mtDNA)
stability.5,6 Despite these essential functions in model sys-
tems, OPA1 mutations in humans cause primarily a
selective degeneration of retinal ganglion cells and optic
atrophy, but 20% of patients develop a diffuse neurologi-
cal syndrome.6,7 Most human OPA1 mutations are non-
sense and frameshift mutations that encode truncated
transcripts prone to degradation by nonsense-mediated
mRNA decay and could therefore produce haploinsuffi-
ciency. The extent of mutant OPA1 transcript depletion
in patients is variable, ranging from no change to an
apparent 60% loss.8
Recently, missense mutations in OPA1 causing
decreased protein expression were associated with parkin-
sonism and cognitive decline,9 suggesting that under cer-
tain conditions, loss of OPA1 function may compromise
dopaminergic cell viability. The mechanism by which
loss of OPA1 leads to cellular dysfunction in human neu-
rons and whether any of these are relevant to disease
severity is unknown. Here, we investigated how loss of
OPA1 attributed to haploinsufficiency impacts on
induced pluripotent stem cell (iPSC)-derived dopaminer-
gic neurons from patients with syndromic parkinsonism
and pure optic atrophy and asked in this tractable model
whether specific functions of OPA1 may associate with
syndromic disease.
Materials and Methods
Reprogramming Donor Fibroblasts to iPSCs
Participants were recruited to this study having given signed
informed consent, which included mutation screening and deri-
vation of human iPSC lines from skin biopsies (Ethics Com-
mittee: National Health Service, Health Research Authority,
NRES Committee South Central, Berkshire, UK, who specifi-
cally approved this part of the study [REC 10/H0505/71]).
The control iPSC lines, AH017-7 and OX3-9, were previously
published.11,12 iPSCs were derived from fibroblasts as described
previously,11 using the SeVdp(KOSM)302L Sendai virus sys-
tem.13 iPSC lines tested negative for mycoplasma using MycoA-
lert (Lonza, Basel, Switzerland).
Assessment of Genome Integrity and Tracking
Genome integrity was assessed by Illumina Human CytoSNP-
12v2.1 beadchip array (300,000 markers), analyzed using Kar-
yoStudio and GenomeStudio software (Illumina, San Diego,
CA). Single-nucleotide polymorphism (SNP) profiles in the
iPSC lines were compared to the corresponding fibroblasts to
confirm their origin and identity.
PluriTest
RNA was extracted from iPSCs using an RNeasy kit (Qiagen,
Hilden, Germany) for Illumina HT12v4 transcriptome array
analysis. Image data files were uploaded to www.pluritest.org
and scored for pluripotency as previously described.14
Flow Cytometry
iPSC lines were assessed for expression of pluripotency markers
by flow cytometry. Cells were lifted with TrypLE (Life Technol-
ogies, Carlsbad, CA), fixed with 4% paraformaldehyde (PFA),
permeabilized in methanol at 220 8C, washed and stained in
flow cytometry buffer with antibody, measured using
fluorescent-activated cell sorting (FACS) Calibur (Becton Dick-
inson, Franklin Lakes, NJ), and analyzed using FlowJo software
(TreeStar, Inc., Ashland, OR). Antibodies used were TRA-1-60
(B119983, IgM-488; BioLegend, San Diego, CA) and
NANOG (D73G4, IgG-647; Cell Signaling Technology, Bev-
erly, MA)
Exome Sequencing and Analysis
DNA was extracted from freshly collected blood samples and
sequenced on Illumina HiSeq 2000. Reads (100 base pair [bp],
paired-end) were mapped to the reference genome (HG19)
using BWA, and variants were called using the Genome Anaysis
Toolkit (GATK) best practice guidelines. Variants were anno-
tated using SnpEFF and filtered using SnpSift and GATK. We
searched for genes that showed nonsynonymous coding variants,
with a minor allele frequency (MAF)< 1% in public databases
(<1% in the 1000 Genomes Project [1KG] and in the Exome
Aggregation Consortium [ExAC] that were present only in the
index case, but not his mother. We further filtered the candidate
genes on the basis of the predicted impact of each variant by
combined annotation-dependent depletion score (>10) and the
number of damaging mutations found in healthy individuals for
each gene by gene-damaging index. Candidate modifiers were
annotated with their expression level in brain using the Gtex data-
base and their haploinsifficiency score (http://nar.oxfordjournals.
org/content/43/15/e101). Genes with known mitochondrial func-
tion were annotated using the MitoCarta database.
Accession Numbers
SNP data sets and Illumina HT12v4 expression array data sets
for the iPSC lines have been deposited in GEO, under Acces-
sion Number GSE94433.
Generation of iPSC-Derived Midbrain
Dopaminergic Neurons
Dopaminergic neurons were derived using a previously pub-
lished protocol with some modifications.15 iPSCs were seeded
onto Geltrex coated six-well plates, expanded until >80% con-
fluency, and mTeSR1 media was changed to day 0 (D0) media
(2 lM of A83-01, 100nM of LDN in neural induction base
medium). D1-4 media contained 2 lM of A83-01, 100nM of
LDN, 300ng/ml of SHH C25II, 2lM of purmorphamine, and
200ng/ml of FGF8a in neural induction base medium. CHIR-
99021 (3 lM) was added from day 3 until day 12. D5-6 media
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contained 100nM of LDN, 300ng/ml of SHH C25II, 2 lM of
purmorphamine, 3 lM of CHIR-99021, and 200ng/ml of
FGF8a in neural induction base medium. D7-10 media con-
tained 100nM of LDN and 3lM of CHIR-99021 in neural
induction base medium. D11-19 medium contained 20ng/ml
of brain-derived neurotrophic factor, 20ng/ml of glial cell line–
derived neurotrophic factor, 1ng/ml of transforming growth fac-
tor beta 3, 10lM of DAPT, 200 lM of ascorbic acid, and
500 lM of dibutyryl-cAMP in neural differentiation media, and
1 lg/ml of of laminin was added from 17 to 25 days of differ-
entiation. At D20, cells were replated into geltrex coated plates,
or coverslips. From D21 media, changes were done with D11
to D19 components until analysis time points (D25, D45, and
D65) were reached.
Immunofluorescence Staining
iPSC-derived neurons were fixed in 4% PFA, permeabilized in
0.3% TritonX-100 in 2% bovine serum albumin, 3% goat
serum containing phosphate-buffered saline, and incubated with
primary antibodies and fluorescently labeled secondary anti-
bodies. The following primary antibodies were used: anti-
Tom20 (FL145, rabbit polyclonal; Santa Cruz Biotechnology,
Santa Cruz, CA), anti-TH (mouse monoclonal; Millipore, Bil-
lerica, MA), anti-bIII tubulin/TUJ1 (mouse monoclonal, BioL-
egend; rabbit polyclonal from Abcam [Cambridge, MA]), anti-
FOXA2 (A12 clone, Santa Cruz Biotech). Images were obtained
using UltraVIEW VoX Spinning Disk Confocal Microscope
(PerkinElmer, Waltham, MA) and analyzed using CellProfiler.
For dopaminergic makers, 30 images (633magnification) were
analyzed for each marker per differentiation per line. For frag-
mentation and mitotracker measurements, 20 to 30 images (at
633) were obtained per time point per clone per differentiation
and >900 cells were analyzed per subject. For cell numbers, at
least 20 images (203magnification) were obtained per time
point per differentiation using immunofluorescence microscopy
(6963 520). Larger clusters that could not be quantified were
excluded by the software, and, in total, >30,000 cells were
counted per subject for cell death measurements.
Electrophysiology
Voltage-clamp recordings were obtained from iPSC-derived
neurons using an Axopatch 200B amplifier (Molecular Devices,
San Jose, CA). For the current clamp recordings 130mM of
KCl, 1mM of MgCl2, 5mM of MgATP, 10mM of HEPES,
and 0.5mM of EGTA (pH7.3) solution was used. Recordings
were obtained at room temperature, with a sampling rate of
5KHz, using the pClamp 10 acquisition software (Molecular
Devices). Data were analysed using MatLab R2015A (The
MathWorks, Inc., Natick, MA).
mtDNA Copy Number and Deletion Levels
Determination and Long-Range PCR
mtDNA was amplified in two fragments of approximately 9.9
kilobases (kb) and 15.4 kb in length using Takara PrimeSTAR
GXL DNA polymerase (Takara Bio Inc., Kusatsu, Japan). Primer
sequences were as follows: 1F: CCCTCTCTCCTACTCCTG
(bp 6,222–6,239), 1R: CAGGTGGTCAAG TATTTATGG (bp
16,133–16,153) and 2F: TTAAAACTCAAAGGACCTGGC
(bp 1,157–1,177), 2R AGGGTGATAGACCTGTGATC (bp
19–1). qPCR was used to amplify mitochondrial genes MTND1
and MTND4 and the nuclear gene, B2M. Control samples with
or without mtDNA deletions were included in all assays. All sam-
ples were assayed in triplicates per qPCR run. mtDNA copy
number (CN) was calculated based on the relative abundance of
MTND1 gene compared to the nuclear gene, B2M. mtDNA
deletion levels were calculated using the comparative threshold
cycle (Ct) method of MTND4 and MTND1 genes.16
Metabolic Studies
Oxygen consumption rates (OCRs) were measured using the
Seahorse XFe96 analyzer (Seahorse Bioscience, North Billerica,
MA) in cells seeded on XFe96 microplates. The Mito stress test
kit (Seahorse Bioscience) was used to monitor OCR. Three
baseline recordings were made, followed by sequential injection
of the ATP synthase inhibitor, oligomycin (3 lM), the mito-
chondrial uncoupler, carbonyl cyanide-4-(trifluoromethoxy)-
phenyl-hydrazone (1.25 lM), and the respiratory chain
inhibitors, antimycin A (0.5 lM) and rotenone (0.5 lM).
Results were corrected for cell numbers using CyQuant (Ther-
moFisher Scientific, Waltham, MA). For complex I enzyme
activity, lysates were incubated with a specific complex I anti-
body precoated on microplates (ab109721; Abcam) and activity
was subsequently determined by following the oxidation of
NADH to NAD1 using a colorimetric assay.
Electron Microscopy
Cells on coverslips were fixed with prewarmed fixative (2.5% glu-
taraldehyde and 2% PFA in 0.1M of PIPES buffer; pH 7.2). Cells
were incubated in 1% osmium tetroxide, overnight in 0.5% ura-
nyl acetate (aqueous), and taken through a graded ethanol series
and gradually infiltrated with Agar100 epoxy resin. Blocks were
polymerized and submerged in liquid nitrogen. Ultrathin (90-
nm) sections were obtained using a Leica UC7 ultramicrotome
with a diamond knife (DiATOME, Hatfield, PA) and placed on
200 mesh copper grids, then poststained with Reynold’s lead cit-
rate and imaged on a FEI Tecnai 12 transmission electron micro-
scope (TEM) operated at 120kV using a Gatan OneView CMOS
camera. Between 15 and 30 images per clone per differentiation
were scored using ImageJ (NIH, Bethesda, MD) software.
Statistical Analysis
The statistical analysis was performed using Prism (GraphPad
Software Inc., La Jolla, CA). Data were analyzed using one-way
analysis of variance (ANOVA). Biological replicates (n) are
defined as differentiations performed at least one cell-split apart,
which is generally 1 week. The number of replicates included
two clones per subject each differentiated three times.
Results
Clinical and Genetic Information
The proband is a 62-year-old male who presented at the
age of 46 with 1-year history of micrographia and
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unilateral tremor on a background of dominantly inher-
ited optic atrophy since his mid-thirties. On examination
at presentation in 2001, he had a mild resting tremor,
moderate rigidity, and bradykinesia on the right upper
limb without any corticospinal, cerebellar features or auto-
nomic involvement. He had a positive DaTScan showing
asymmetric left-sided dopaminergic loss (Fig 1). He did
not respond to dopamine agonists or levodopa therapy
and progressed significantly within 6 months with inabil-
ity to write and unsteadiness attributed to a rigid right leg,
requiring support with a stick. His examination revealed
progression of the extrapyramidal signs with bilateral
asymmetric involvement of both upper and lower limbs,
worse on the right. Within 2 years of his initial diagnosis,
he developed frequent falls, walked with a broad-based fes-
tinant gait, and had impaired postural reflexes. There was
no objective improvement with subcutaneous apomor-
phine. He became wheelchair bound within 6 years from
the initial presentation. He stopped working at the age of
48. His estimated premorbid IQ was 110 and his cognitive
profile, recognition memory, and non-verbal memory as
documented at 10 years postdiagnosis were in line with
estimates of his premorbid ability. He developed some
swallowing difficulties, occasional visual hallucinations,
and suffered from low mood when assessed 14 years post-
diagnosis. His brain magnetic resonance imaging (MRI) at
presentation was normal. He had normal motor and sen-
sory nerve conduction on neurophysiology. His mother
suffered with progressive visual loss since the second
decade of her life with documented optic atrophy and
passed away at the age of 87. When assessed at the age of
84, she did not have any other neurological deficits and
was very independent in her daily activities living alone
despite her visual problems. During the last 3 years of her
life, her condition deteriorated with balance problems and
memory decline. She was using the wheelchair only during
the last 12 months of her life. Genetic testing in both
cases revealed a novel insertion in exon 2 of 3 in-frame
codons (c.33-34ins9), the second of which is a stop
codon predicted to result in OPA1 haploinsufficiency
(Fig 1A). Common POLG and mtDNA mutations were
negative in blood, and no mutations were identified in
genes implicated in familial parkinsonism. The second
OPA1 allele was sequenced in both cases and was normal
without any of the intronic OPA1 mutations that have
been reported to act as modifiers in some cases with syn-
dromic OPA1 disease.10 To identify candidate modifier
genes, we performed whole-exome sequencing searching
for genes that showed nonsynonymous coding variants,
with a MAF that were present only in the index case but
not his mother. We identified a total of 54 variants in 54
genes that met these criteria. Nine of the genes identified
(ATG4C, CENPJ, ERCC3, SH3GLB2, TSC1, HNRNPU,
PIN1, NT5M, and HSPBP1) are expressed in neuronal
tissues, but none of the variants identified are known to
be pathogenic.
FIGURE 1: Clinical information. (A) Family treeof the indexcasewhopresentedat theageof46with syndromicparkinsonismandhismother
whomanifestedwith pure optic atrophy until the ageof 84. TheOPA1mutation consistedof a 9basepair insertion introducing a stop codon
in exon 2 leading to haploinsufficiency. (B) Bilateral optic atrophy in index case. (C) DaTScan showing evidence of asymmetric dopaminergic
cell loss in the index case. (D) Recent CT brain of the index case showingmild generalised involutional changes without signal change within
thebasal ganglia. CT5 computed tomography;OPA15optic atrophy1. [Color figure canbe viewedatwileyonlinelibrary.com]
ANNALS of Neurology
4 Volume 00, No. 00
Generation and Characterization of Human iPSC
Lines
We generated two human iPSC clonal lines from fibro-
blasts obtained from each of the 2 patients with OPA1
haploinsufficiency and compared them to iPSC from 2
healthy controls (Table). Detailed characterization of the
OPA1 lines and the newly derived healthy lines used in
this study is shown in Figure 2. Genome integrity and
FIGURE 2: Generation of iPSC lines. (A) Karyograms for each iPSC line and original fibroblasts. (B) Human iPSC lines exhibited pluripo-
tent stem cell-likemorphology by phasemicroscopy in feeder-free culture; scale bar5100mm; Right panel, FACS analysis of iPSC for plu-
ripotency markers Tra-1-60 and Nanog (black line); grey filled plot, isotype control. (C) PluriTest analysis showed that the iPSC lines
cluster with pluripotent stem cells (top left quadrant). Each circle represents one iPSC line y-axis pluripotency score, x-axis novelty score.
FACS5 fluorescence-activated cell sorting; iPSC5 induced pluripotent stem cell. [Color figure can be viewed at wileyonlinelibrary.com]
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FIGURE 3: iPSC-derived dopaminergic neurons from syndromic OPA1 parkinsonism recapitulate disease severity. (A) Immunos-
taining for TH, FOXA2, and TUJ1 was readily detected across controls and patient lines, scale bar 30lm. (B) Quantification at
D45 revealed equal percentage of FOXA2-, TUJ1-, and TH-positive cells across lines. (C) Representative example of iPSC
derived dopaminergic neuron at DIV65, showing repetitive spiking in response to a 400ms depolarizing pulse (D) Quantifica-
tion of immunoblotted OPA1 protein revealed marked reduction in both patient lines at all time-points tested. (E) Accelerated
cell death was detected in clones of iPSC-derived dopaminergic neurons from the patient with syndromic disease when cul-
tured for D45 and D65, scale bar 150lm. (F) Quantification of the percentage of cells remaining at D45 and D65 compared to
D25. Data are mean6SEM and biological replicates are defined as individual clone differentiations using two clones per sub-
ject each differentiated three times. HC5healthy control. Analysis was done using one-way ANOVA (**p<0.01; ***p<0.001;
****p<0.0001). ANOVA5analysis of variance; iPSC5 induced pluripotent stem cell; OPA15optic atrophy 1; SEM5 standard
error of the mean.
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tracking to the original patient sample was confirmed by
Illumina SNP array (Fig 2A). All iPSC lines displayed
embryonic stem cell–like morphology and expressed the
pluripotency-associated proteins, TRA-1-60 and Nanog
(Fig 2B). Conformity to a pluripotent expression profile
was shown by PluriTest (Fig 2C).
Progressive Neuronal Loss in syndromic OPA1
Disease Is Recapitulated in iPSC-Derived
Cultures
To study the effect of the OPA1 haploinsufficinecy in
the context of parkinsonism, two iPSC clones from each
of the 2 controls and the 2 patients were each differenti-
ated three times into dopaminergic neuronal cultures.
Results from lines derived from the patient with syn-
dromic OPA1 parkinsonism are denoted as Opa1P,
whereas lines derived from the patient with optic atrophy
are represented as Opa1. We confirmed by immunofluo-
rescence that in all lines, dopaminergic neurons coex-
pressed the floor plate marker, FOXA2, with TH or b-3
tubulin (TUJ1) with TH (Fig 3A). Differentiation effi-
ciency, as assessed by the immunofluorescence for
FOXA2, b-3 tubulin, and TH, was similar across the
genotypes used with approximately 80% of cells
FIGURE 4: OPA1 haploinsufficiency causes progressive OXPHOS defect in iPSC-derived neurons. (A) Extracellular flux analysis
at D25 and D65 revealed a progressive decline in OCR, maximal respiration and ATP production in both patient lines. (B)
Immunoblotting for mitochondrial proteins revealed a progressive decline in complex I in OPA1 haploinsufficient lines, which
was quantified in (C). (D) Complex I activity was reduced in OPA1 hapoinsufficient lines compared to controls. (E) Morphomet-
ric analysis of the ratio of surface area of cristae to corresponding mitochondrial segment or mitochondrial width. Each dot
represents the average of at least 15 randomly selected images from each clone. Quantification in all panels is based on two
clones per subject each differentiated three times. Data are mean6SEM and analysed using One-way ANOVA (*p<0.05;
**p<0.01; ****p<0.0001). ANOVA5 analysis of variance; HC5healthy control; iPSC5 induced pluripotent stem cell;
OCR5oxygen consumption rate; OPA15optic atrophy 1; SEM5 standard error of the mean.
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expressing b-3 tubulin and 70% expressing TH (Fig 3B).
At day in vitro (DIV) 65, current-clamp recordings
showed that neurons were able to fire repetitive action
potentials in response to current injection (Fig 3C). Both
patient lines exhibited markedly reduced OPA1 protein
levels when compared to controls (Fig 3D). We found
accelerated neuronal death in the Opa1P patient when
compared to Opa1 or control lines at DIV 45 and 65
(Fig 3E,F), recapitulating the degeneration of neurons
detected by DaTScan in the patient. The absence of a
secondary pathogenic mutation on exome sequencing of
patient DNA to explain this phenotypic difference
between Opa1P and Opa1 lines suggests that syndromic
OPA1 parkinsonism may arise from a modifier effect of
the primary mitochondrial defect. We therefore asked
how functions that were previously ascribed to OPA1 are
manifested in Opa1 and Opa1P lines.
OPA1 Haploinsufficiency Leads to Defective
Oxidative Phosphorylation and Reduced
Complex I Function in iPSC-Derived Neurons
To assess whether OPA1 haploinsufficiency impairs bio-
energetic demand, we performed extracellular flux analy-
sis of OCR. This revealed that loss of OPA1 in iPSC-
derived neurons led to lower basal and maximal OCR
compared to controls at a late (DIV65), but not early
(DIV25), time point, mechanistically suggesting a pro-
gressive defect in electron transport in both Opa1P and
Opa1 lines (Fig 4A). Bioenergetic failure was associated
with loss of complex I as assessed by NDUFV2 levels rel-
ative to actin (Fig 4B,C) and a defect in complex I activ-
ity (Fig 4D) in both patients compared to controls.
Notably, mitochondrial mass based on Tom20 levels rela-
tive to actin and complex V based on ATP5A levels rela-
tive to actin were unchanged across time points and lines
FIGURE 5: iPSC and iPSC-derived neurons do not exhibit mtDNA deletions or copy number variations. (A) Left panel:
MtDNA copy number (CN) per cell measurement showing the mean with standard error of the mean calculated from six inde-
pendent assays using two clones per subject. Right panel: Correlation of ND1 and ND4 Ct values in neurons showing a strong
correlation (Pearson r50.9887) and implying that no deletions in mtDNA were present. An asterisk represents a deletion con-
trol. Gels show representative images of long-range PCR analysis on DNA isolated from iPSC-derived neurons (B) and iPSC
lines (C). bp5base pair; Ct5 threshold cycle; iPSC5 induced pluripotent stem cell; mtDNA5mitochondrial DNA; Opa15optic
atrophy 1.
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(Fig 4B). Despite this clear functional deficit, we did not
detect overt changes in the morphology of the mitochon-
dria or cristae when assessed by TEM at either early or
late time points (DIV25/45/85, not shown) and illus-
trated here at DIV65 (Fig 4E). mtDNA analysis did not
reveal any deletions in the patient-derived neurons (Fig
5) as previously reported in skeletal muscle.5,6 Thus,
reduced OPA1 protein levels in iPSC-derived neurons
cause a delayed defect in oxidative phosphorylation,
which is most likely at the level of complex I.
Mitochondrial Fragmentation in iPSC-Derived
Neurons Correlates With Clinical Severity in
Patients
To investigate the relevance of OPA1-mediated mito-
chondrial fusion in our model, we assessed the mitochon-
drial network by quantifying the percentage of neurons
with fragmented or filamentous Tom20-positive mito-
chondria. This analysis showed that by DIV65, fragmen-
tation was increased in the Opa1P lines compared to
either Opa1 or controls (Fig 6A,B). Accordingly, the
abundance of the cleaved (short) S-OPA1 isoform, which
typically accumulates in cells with fragmented mitochon-
dria, was increased in Opa1P neurons (Fig 6C). When
assessed as individual networks using the ratio of mito-
tracker Red to Tom20, the fragmented mitochondrial
segments in Opa1P neurons exhibited reduced uptake
and thus impaired function at DIV65 (Fig 6D,E).
Discussion
Despite the multifactorial role of OPA1 in mitochondrial
health, loss of its function commonly causes autosomal-
dominant optic atrophy and, only under certain condi-
tions, leads to a systemic mitochondrial disease. What is
its critical function in human neurons and how this is
linked to neuronal vulnerability to cell death is currently
unclear. Using an iPSC-based model, we showed that
loss of OPA1 causes a late-onset deficit in oxidative
phosphorylation and a differential loss of mitochondrial
fusion, which associates with disease severity. Unlike
FIGURE 6: Mitochondrial fragmentation in iPSC-derived neurons associates with severity of clinical phenotype in patients. (A)
Progressive fragmentation of Tom20-positive mitochondria was detected by D65 in Opa1P lines. (B) Quantification of the per-
centage of neurons with fragmented mitochondria networks. (C) The abundance of cleaved (short) S-OPA1 isoform was
increased in Opa1P neurons. (D–E) Mitochondria in Opa1P exhibited reduced uptake of mitotracker. Quantification in all pan-
els is based on two clones per subject each differentiated three times. Data are mean6SEM and analysed using one-way
ANOVA (*p<0.05; **p<0.01; ****p<0.0001). Scale bar, 20lm. ANOVA5analysis of variance; HC5healthy control; iPSC5 in-
duced pluripotent stem cell; Opa15optic atrophy 1; SEM5 standard error of the mean.
Jonikas et al: iPSC modeling of OPA1 disease
Month 2018 9
earlier OPA1 knockdown studies in cell lines,3,17 we did
not observe marked disorganization of the morphology of
the mitochondria or their cristae in patient-derived neu-
rons. This discrepancy is most likely attributed to the fact
that previous studies in cell lines have examined the conse-
quences of acute and/or complete depletion of OPA1
within 24 to 72 hours3,17 instead of pathophysiologically
relevant OPA1 levels as in our patient-derived neuronal
model, where the defect developed over 45 to 65 days.
This scenario is in agreement with the slowly progressive
focal neurological phenotype in most patients with OPA1
haploinsufficiency.7 It is possible that under conditions of
neuronal stress, the ultrastructural morphology of OPA1
haploinsufficient mitochondria is disorganized before cell
death and our TEM studies have not captured such events.
Instead, our data suggest that a late defect in complex I
may account for the reduction of electron transport across
the respiratory chain as evidenced by the decreased maxi-
mal respiration in mutant neurons and the reduction of
complex I levels and activity. Functional changes in com-
plex I were previously reported in fibroblasts with OPA1
haploinsufficiency18 or the p.G488R mutation9 and in
models of acute OPA1 depletion, where respiratory effi-
ciency was impaired when mitochondria were energized
specifically with the complex I substrates, glutamate/
malate.17 Therefore, in human iPSC-derived neurons,
OPA1 levels are important for the maintenance of oxida-
tive phosphorylation, at least partly, by regulating the sta-
bility of complex I.
In the context of syndromic disease, impaired regu-
lation of oxidative phosphorylation and complex I defi-
ciency was not sufficient to explain the differential
viability of dopaminergic neurons between Opa1P and
Opa1 lines. Interestingly, clinicopathological studies in
patients with POLG mutations also found that complex I
deficiency did not correlate with parkinsonian features.19
Given that fragmentation has been associated with apo-
ptosis,20 the cell death in culture could be, at least partly,
determined by the exacerbated mitochondrial
fragmentation in Opa1P lines, which also exhibited
increased proteolytic processing of L-OPA1 to the short
isoform. Proteolytic cleavage of L-OPA1 is regulated by
either YME1L1, which is under metabolic control21 or
OMA1, which is activated upon various stress insults,
resulting in the complete degradation of L-OPA1 and
mitochondrial fragmentation.22,23 Interestingly, in a
mouse model of neurodegeneration, L-OPA1 promoted
neuronal survival without affecting cristae shape, whereas
stress-induced OMA1 activation and L-OPA1 cleavage
increased mitochondrial fragmentation and promoted
neuronal death.24
Further investigation is required to determine
which cellular stressors or adaptive mechanisms promote
or oppose OPA1-mediated mitochondrial fragmentation
in syndromic OPA1 disease and potentially other com-
mon diseases. Our initial whole-exome analysis did not
identify a secondary mutation of known pathogenicity,
but does not exclude the contribution of multiple minor
genetic determinants such as effects on autophagy, which
is activated in cells carrying a mutant OPA1 allele9,25 or
microtubule-associated transport, which is important for
axonal mitochondrial motility. This withstanding, our
finding that key cellular phenotypes are reproduced in
vitro suggests, for the first time, that syndromic disease
may arise from genetic modifiers that exacerbate the
mitochondrial defect, which, at least in dopaminergic
neurons, manifested as OPA1-mediated mitochondrial
fragmentation. It is possible that different mechanisms
operate in other subtypes of syndromic OPA1-mediated
disease. Nevertheless, understanding how L-OPA1 proc-
essing varies in syndromic OPA1 and common diseases
of dopaminergic cell loss such as Parkinson’s and promot-
ing L-OPA1 stability (eg, by OMA1 inhibition) could
pave the way for novel targeted therapies against mito-
chondrial dysfunction in neurodegeneration. More
broadly, our study demonstrates how deep-phenotyping
of a rare disease using iPSCs can help contextualize key
functions of essential mitochondrial proteins in the study
TABLE . Summary of the Lines Used in This Study
ID Sex Age at Biopsy No. of iPSC clones Original ID Characterization
Control 1 Male 49 2 OX3-6 OX3-9 This study Dafinca et al 2016
Control 2 Female 67 2 AH017-3 AH017-7 Handel et al 2016
OPA1 Female 84 2 OPA1-9 OPA1-11 This study
OPA1P Male 62 2 OPA1P-2 OPA1P-5 This study
Two clones per subject were used each differentiated three times.
iPSC5 induced pluripotent stem cell; OPA15 optic atrophy 1.
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of disease severity, which is an important step toward
personalized neurology, and suggests that mapping of
genetic modifiers could have prognostic significance.
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